|
|
Volumn 6, Issue 3, 2005, Pages 202-204
|
|
Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CERIVASTATIN;
DEXFENFLURAMINE;
DRUG;
FENFLURAMINE;
ISOTRETINOIN;
PLACEBO;
ROFECOXIB;
SALMETEROL XINAFOATE;
SEROTONIN UPTAKE INHIBITOR;
SIBUTRAMINE;
VALDECOXIB;
XIMELAGATRAN;
ACNE;
ARTHRITIS;
ASTHMA;
CLINICAL TRIAL;
COLON CANCER;
COLON POLYP;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG INFORMATION;
DRUG MARKETING;
DRUG SAFETY;
DRUG SURVEILLANCE PROGRAM;
DRUG WITHDRAWAL;
FOOD AND DRUG ADMINISTRATION;
HEART INFARCTION;
HUMAN;
HYPERCHOLESTEROLEMIA;
HYPERLIPIDEMIA;
INFORMATION SYSTEM;
LICENCE;
LIVER DISEASE;
MALIGNANT TRANSFORMATION;
MEDICAL DECISION MAKING;
MEDICAL ETHICS;
METHODOLOGY;
NOTE;
OBESITY;
ONLINE SYSTEM;
PATIENT MONITORING;
PATIENT SELECTION;
PHARMACOGENOMICS;
PHYSICIAN ATTITUDE;
POSTMARKETING SURVEILLANCE;
PRESCRIPTION;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
RISK MANAGEMENT;
RISK REDUCTION;
SIDE EFFECT;
STROKE;
UNITED STATES;
CLINICAL TRIALS;
DRUG APPROVAL;
HUMANS;
LACTONES;
PHARMACEUTICAL PREPARATIONS;
PRODUCT SURVEILLANCE, POSTMARKETING;
SULFONES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 16844374093
PISSN: 1469221X
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.embor.7400353 Document Type: Note |
|
Times cited : (28)
|
|
References (7)
|
